Catheter ablation with power titration according to contact force in patients undergoing pulmonary vein isolation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0002517

Enrollment

100

Registered

2017-11-03

Start date

2017-11-10

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : All patients are undergoing to PV isolation using smart-touch surround flow catheter - Power titration according to contact force o Power titration according to contact force ((&l

10g: 35-45 W

11~30g: 25-35 W

31-50g:15-25 W

&gt

51g:5-15 W) o point-by-point ablation o LA posterior wall facing esophagus,: 20-25 W, 15-20 seconds, 10-20 g - Standard PV isolation o Target contact force: 10-40 gram o 30 W 20 sec ablation (power m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age =18 years, = 80 years 2) Atrial fibrillation, paroxysmal or persistent ( < 1 year in duration) which documented on the electrocardiography (12-lead electrocardiography, holter monitoring, or telemetry monitoring) 3) Refractory or intolerant to class I or III antiarrhythmic drug(s) 4) providing informed consent to radiofrequency ablation for atrial fibrillation

Exclusion criteria

Exclusion criteria: 1) Atrial fibrillation from transient reversible cause 2) Coagulopathy 3) Pregnancy 4) Longstanding persistent atrial fibrillation ( >1 year) 5) Atypical atrial flutter 6) Prior catheter or surgical ablation of atrial fibrillation 7) Prior open heart surgery from any cause 8) Acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypas grafting within 3 months 9) mitral or aortic valvular heart disease more than moderate degree 10) Large left atrial size (anterior-posterior diameter more than 50mm) 11) Presence of thrombus in left atrium or appendage 12) Significant hematologic disorder (leukocyte count < 3000/mm3, or thrombocytopenia < 100,000/mm3) 13) Significant liver dysfunction 14) Significant renal dysfunction 15) Contraindications to the anticoagulation 16) Left ventricular ejection fraction less than 45% 17) A patient who currently enrolled in other randomized clinical study (except registry) 18) A patient with other significant comorbidity whom is deemed not suitable to participate in the current study

Design outcomes

Primary

Measure	Time frame
Presence of dormant conduction provoked with 12mg of intravenous adenosine injection after pulmonary vein isolation	—

Secondary

Measure	Time frame
Recurrence of atrial fibrillation or flutter	—

Countries

Korea, Republic of

Contacts

Public ContactMin Soo Cho

Asan Medical Center

d070294@gmail.com+82-2-3010-1327

Outcome results